Latest News

"It is now essential other wealthy countries step up their contribution to fund innovation,” said AstraZeneca CEO Pascal Soriot, announcing the agreement with the Trump administration.

This is an unedited transcript of the exchange late last night at Senate Estimates between health department officials and Shadow Health Minister Senator Anne Ruston on the Health Technology Assessment Review.

The program has been unveiled for the AusBiotech International Conference 2025, confirming the most ambitious lineup in the event’s history, with over 60 sessions and 250 speakers set to gather the global life sciences community in Melbourne from 21 to 24 October at the Melbourne Convention and Exhibition Centre.

Australia’s life sciences industry has called for a stronger focus on clinical trials, commercialisation, and investment attraction in the federal government’s forthcoming National Health and Medical Research Strategy.

The Therapeutic Goods Administration has responded to questions about ongoing shortages of some ADHD medications in response to questions at Senate Estimates.

The comparatively modest growth in pharmaceutical spending can be attributed to two decades of policy restraint, including price reduction mechanisms and tighter management of PBS listings.

Dimerix has received final data from the PARASOL collaboration, reinforcing support for the company’s proteinuria-based endpoints in its Phase 3 ACTION3 study for Focal Segmental Glomerulosclerosis.

Global pharmaceutical leaders CSL and AbbVie have joined as strategic partners to help propel the next generation of Australian biotech ventures.

New Zealanders are missing out on access to 142 modern medicines that are publicly funded in Australia, and the vast majority are not optional or investigational.

Mental health remains the top reason Australians visit their GP, with 71 per cent of practitioners citing anxiety and depression as their most common presentations.

AusBiotech has released its 2024–25 Annual Report, marking what Chair Dr James Campbell described as a “transformational and defining year” for the organisation and Australia’s broader life sciences community.

AstraZeneca has followed others in saying it could suspend further investment in the United Kingdom unless the government reforms what its chairman described as an “antiquated and appalling” drug pricing system.